Arbutus Biopharma Corp
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease, with development programs for chronic hepatitis B (cHBV). Its two product candidates are imdusiran, a subcutaneously delivered RNA interference therapeutic designed to reduce hepatitis B viral… From the company’s description.
Over the twelve months to Jun 30, 2026, Arbutus Biopharma Corp reported revenue of $181.72M, up 1078.8% from a year earlier, and net income of $153.05M. Its operating margin was 82.0%, and operations used $24.63M in cash. In fiscal 2025, it reported revenue of $14.08M, up 128.2% from fiscal 2024, and a net loss of $33.50M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Arbutus Biopharma Corp does
In the company’s own words
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease, with development programs for chronic hepatitis B (cHBV). Its two product candidates are imdusiran, a subcutaneously delivered RNA interference therapeutic designed to reduce hepatitis B viral antigens, and AB-101, an oral PD-L1 inhibitor intended to activate patients’ HBV-specific immune response; both are in clinical development. The company has no product sales and also earns revenue through licensing and royalty rights related to its lipid nanoparticle (LNP) delivery technology, including royalties on sales of ONPATTRO and payments from partners using the technology. Arbutus retains LNP and conjugate delivery rights for HBV and licenses other applications to Genevant Sciences, in which it also holds an equity interest. It pursues its cHBV programs directly and through collaborations, and has granted and later regained global rights to imdusiran after terminating its China-region partnership with Qilu in 2025. The company reported $0.5 million in revenue for 2025 from an LNP-related milestone. Its website is www.arbutusbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WARMINSTER, PA
- Fiscal year end
- December
- CIK
- 1447028
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Arbutus Biopharma Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Arbutus Biopharma Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Arbutus Biopharma Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Arbutus Biopharma Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Arbutus Biopharma Corp's last four quarterly filings that the numbers alone won't show?”